Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Increasing telmisartan vs amlodipine dose in patients with hypertension, type 2 diabetes and microalbuminuria

Nature Clinical Practice Nephrology volume 3, pages 476–477 (2007)Cite this article

boxed-textFogari R et al. (2007) Effect of telmisartan–amlodipine combination at different doses on urinary albumin excretion in hypertensive diabetic patients with microalbuminuria. Am J Hypertens 20: 417–422

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Lewis EJ et al. (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851–860

    Article  CAS  Google Scholar 

  2. Parving HH et al. (2001) The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345: 870–878

    Article  CAS  Google Scholar 

  3. Pohl MA et al. (2005) Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. J Am Soc Nephrol 16: 3027–3037

    Article  CAS  Google Scholar 

  4. Schmieder RE et al. (2005) Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study. J Am Soc Nephrol 16: 3038–3045

    Article  CAS  Google Scholar 

  5. Rossing K et al. (2005) Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int 68: 1190–1198

    Article  CAS  Google Scholar 

  6. Chobanian AV et al. (2003) Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42: 1206–1252

    Article  CAS  Google Scholar 

  7. Glassock RJ (2006) Prevention of microalbuminuria in type 2 diabetes: millimeters or milligrams? J Am Soc Nephrol 17: 3276–3278

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Chloë Harman, Associate Editor, Nature Clinical Practice.

Author information

Author notes

  1. Division of Nephrology, Vanderbilt University, Medical Center, S-3223 Medical Center North Nashville, TN 37232–2372 USA julia.lewis@vanderbilt.edu

Authors and Affiliations

  1. J Lewis is a Professor of Medicine in the Division of Nephrology at Vanderbilt University, Nashville, TN, USA.,

    Julia Lewis

Authors
  1. Julia Lewis
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lewis, J. Increasing telmisartan vs amlodipine dose in patients with hypertension, type 2 diabetes and microalbuminuria. Nat Rev Nephrol 3, 476–477 (2007). https://doi.org/10.1038/ncpneph0562

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpneph0562

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing